About Syndax
Syndax is a company based in Waltham (United States) founded in 2005.. Syndax has raised $198.29 million across 11 funding rounds from investors including Fidelity Investments, Orbimed and ArrowMark Partners. The company has 270 employees as of December 31, 2024. Syndax offers products and services including Revumenib and Axatilimab. Syndax operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Waltham, United States
- Employees 270 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Syndax Pharmaceuticals, Inc.
-
Annual Revenue
$23.68 M0as on Dec 31, 2024
-
Net Profit
$-318.76 M-52.25as on Dec 31, 2024
-
EBITDA
$-339.66 M-47.72as on Dec 31, 2024
-
Total Equity Funding
$198.29 M (USD)
in 11 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Jan 31, 2020
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
270
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Syndax
Syndax is a publicly listed company on the NASDAQ with ticker symbol SNDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Syndax
Syndax offers a comprehensive portfolio of products and services, including Revumenib and Axatilimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigates treatments for acute leukemias and genetic mutations.
Targets graft-versus-host disease and pulmonary fibrosis conditions.
Unlock access to complete
Unlock access to complete
Leadership Team
37 people
Product Management Team
5 people
Legal and Compliance
5 people
Finance and Accounting
5 people
Human Resources and Administration
4 people
Operations Team
3 people
Data Analysis and Operations Team
3 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Syndax
Syndax has successfully raised a total of $198.29M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $35.0M
-
First Round
First Round
(03 Apr 2007)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Post-IPO - Syndax | Valuation |
investors |
|
| Aug, 2015 | Amount | Series C - Syndax | Valuation | Fidelity Investments , Delos Capital Partners | |
| Jun, 2015 | Amount | Series B - Syndax | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Syndax
Syndax has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Orbimed and ArrowMark Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm that does early stage investments in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Syndax
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Syndax
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Syndax Comparisons
Competitors of Syndax
Syndax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Syndax
Frequently Asked Questions about Syndax
When was Syndax founded?
Syndax was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Where is Syndax located?
Syndax is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Syndax a funded company?
Syndax is a funded company, having raised a total of $198.29M across 11 funding rounds to date. The company's 1st funding round was a Series B of $23.96M, raised on Apr 03, 2007.
How many employees does Syndax have?
As of Dec 31, 2024, the latest employee count at Syndax is 270.
What is the annual revenue of Syndax?
Annual revenue of Syndax is $23.68M as on Dec 31, 2024.
What does Syndax do?
Syndax was founded in 2005 and is headquartered in Waltham, United States. Operations are centered in the biotechnology sector, where targeted therapies for oncology are advanced. Entinostat is being developed as a combination treatment for various cancer types, with primary attention given to immunotherapy-responsive tumors such as those in lung cancer, melanoma, and triple-negative breast cancer.
Who are the top competitors of Syndax?
Syndax's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Syndax offer?
Syndax offers Revumenib and Axatilimab.
Is Syndax publicly traded?
Yes, Syndax is publicly traded on NASDAQ under the ticker symbol SNDX.
Who are Syndax's investors?
Syndax has 15 investors. Key investors include Fidelity Investments, Orbimed, ArrowMark Partners, EcoR1, and Jennison Associates.
What is Syndax's ticker symbol?
The ticker symbol of Syndax is SNDX on NASDAQ.